SG165414A1 - Glp-1 ( glucagon-like peptide-1 ) fusion polypeptides with increased peptidase resistance - Google Patents
Glp-1 ( glucagon-like peptide-1 ) fusion polypeptides with increased peptidase resistanceInfo
- Publication number
- SG165414A1 SG165414A1 SG201006921-9A SG2010069219A SG165414A1 SG 165414 A1 SG165414 A1 SG 165414A1 SG 2010069219 A SG2010069219 A SG 2010069219A SG 165414 A1 SG165414 A1 SG 165414A1
- Authority
- SG
- Singapore
- Prior art keywords
- glp
- peptide
- component
- sequence
- glucagon
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 title abstract 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 5
- 230000004927 fusion Effects 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000034615 apoptosis-related disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05020718A EP1767545B1 (fr) | 2005-09-22 | 2005-09-22 | Polypeptides de fusion de glp-1 (peptide 1 de type glucagon) ayant une resistance accrue a la peptidase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG165414A1 true SG165414A1 (en) | 2010-10-28 |
Family
ID=35700191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201006921-9A SG165414A1 (en) | 2005-09-22 | 2006-09-22 | Glp-1 ( glucagon-like peptide-1 ) fusion polypeptides with increased peptidase resistance |
Country Status (23)
Country | Link |
---|---|
US (2) | US8431533B2 (fr) |
EP (5) | EP1767545B1 (fr) |
JP (2) | JP5222729B2 (fr) |
KR (1) | KR20080064840A (fr) |
CN (1) | CN101273058A (fr) |
AT (1) | ATE448247T1 (fr) |
AU (1) | AU2006299134B2 (fr) |
BR (1) | BRPI0616107A2 (fr) |
CA (1) | CA2619053A1 (fr) |
CY (1) | CY1109778T1 (fr) |
DE (1) | DE602005017628D1 (fr) |
DK (1) | DK1767545T3 (fr) |
EA (1) | EA013796B1 (fr) |
ES (3) | ES2336575T3 (fr) |
HR (1) | HRP20100062T1 (fr) |
IL (1) | IL188904A0 (fr) |
PL (1) | PL1767545T3 (fr) |
PT (1) | PT1767545E (fr) |
RS (1) | RS51319B (fr) |
SG (1) | SG165414A1 (fr) |
SI (1) | SI1767545T1 (fr) |
WO (1) | WO2007039140A1 (fr) |
ZA (1) | ZA200803488B (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
JP2009513627A (ja) * | 2005-10-27 | 2009-04-02 | ペプトロン カンパニー リミテッド | 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法 |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (fr) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
EP1975176A1 (fr) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Nouveaux peptides à fusion GLP-1, leur production et utilisation |
EP2926825A1 (fr) * | 2008-06-27 | 2015-10-07 | Duke University | Agents thérapeutiques comprenant des peptides de type élastine |
EP2163243A1 (fr) * | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Traitement de l'infarctus du myocarde (AMI) utilisant des cellules encapsulées codant et sécrétant des peptides GLP-1 ou analogues associés |
CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
KR101485646B1 (ko) * | 2010-02-11 | 2015-01-22 | 에프. 호프만-라 로슈 아게 | Igf―ⅰ 폴리(에틸렌 글리콜) 컨쥬게이트 |
US20130225508A1 (en) * | 2010-10-01 | 2013-08-29 | Osamu Masaki | Peptide capable of binding to immunoglobulin |
CN102766204B (zh) * | 2011-05-05 | 2014-10-15 | 天津药物研究院 | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 |
CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
EP3434696A1 (fr) | 2012-11-20 | 2019-01-30 | Mederis Diabetes, LLC | Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline |
CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
CN104707131A (zh) * | 2013-12-13 | 2015-06-17 | 上海建华精细生物制品有限公司 | 一种药物组合物及其制备方法和用途 |
CN117180445A (zh) | 2014-05-28 | 2023-12-08 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
WO2016127887A1 (fr) | 2015-02-11 | 2016-08-18 | 杭州鸿运华宁生物医药工程有限公司 | Préparation de solution stabilisée de protéine de fusion d'anticorps glp-1r pharmaceutique |
PL3393496T3 (pl) | 2015-12-23 | 2024-04-22 | The Johns Hopkins University | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
CN107818433B (zh) * | 2016-09-14 | 2022-07-05 | 菜鸟智能物流控股有限公司 | 取件方法、物流信息处理方法及装置、系统 |
JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア/エス | アシル化glp−1/glp−2二重アゴニスト |
WO2018104559A1 (fr) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Agonistes doubles de glp-1/glp-2 |
WO2018104558A1 (fr) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Agonistes doubles de glp-1/glp-2 acylés |
CN108341880B (zh) * | 2017-01-23 | 2023-07-04 | 天津药物研究院有限公司 | 含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途 |
KR101827245B1 (ko) * | 2017-12-26 | 2018-02-08 | (주)제이유타이드 | 알라린을 주성분으로 하는 요독증 치료제 |
IL311775A (en) | 2018-01-03 | 2024-05-01 | Mederis Diabetes Llc | Improved peptide drugs for the treatment of NASH and other disorders |
KR101903564B1 (ko) * | 2018-01-31 | 2018-11-13 | 한국지질자원연구원 | 제지공정에서 발생되는 부산물의 재활용 방법 |
HUE060135T2 (hu) | 2018-04-05 | 2023-02-28 | Sun Pharmaceutical Ind Ltd | Új GLP-1 analógok |
CA3123979A1 (fr) | 2018-12-21 | 2020-06-25 | Jiangsu Hengrui Medicine Co., Ltd. | Proteine bispecifique |
KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
EP4119571A4 (fr) * | 2020-03-12 | 2024-04-03 | Sl Metagen | Nouvelle protéine bispécifique et son utilisation |
KR20220008788A (ko) * | 2020-07-14 | 2022-01-21 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도 |
GB2616223A (en) * | 2020-11-27 | 2023-08-30 | D&D Pharmatech Inc | Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
GB2617717A (en) * | 2020-11-27 | 2023-10-18 | D&D Pharmatech Inc | Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
CN112661862B (zh) * | 2020-12-25 | 2023-03-31 | 深圳大学 | 一种融合蛋白及其制备方法和应用 |
CN113846124A (zh) * | 2021-09-26 | 2021-12-28 | 康霖生物科技(杭州)有限公司 | 一种用于糖代谢相关疾病基因治疗的核酸构建体 |
CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US586128A (en) * | 1897-07-13 | Toilet-paper holder | ||
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
DE2966763D1 (de) | 1979-10-16 | 1984-04-12 | Stocker Winfried | Microanalytic device |
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
DD224119A1 (de) | 1983-11-07 | 1985-06-26 | Univ Schiller Jena | Temperierbarer probentraeger |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US5144139A (en) | 1985-08-05 | 1992-09-01 | Biotrack, Inc. | Capillary flow device |
US4687529A (en) | 1985-08-30 | 1987-08-18 | Miles Laboratories, Inc. | Method of making a reagent test device containing hydrophobic barriers |
CA1292176C (fr) | 1985-09-18 | 1991-11-19 | Joel M. Blatt | Dispositif volumetrique a orifice capillaire pour la deposition d'un echantillon liquide sur une surface reactive |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
ES2087323T3 (es) | 1991-02-19 | 1996-07-16 | Takeda Chemical Industries Ltd | Metodo para producir peptidos exentos de cisteina. |
CA2062338A1 (fr) | 1991-03-15 | 1992-09-16 | Zia Yassinzadeh | Cartouche de commande electronique et methode de simulation de diagrammes de transmission lumineuse |
GB9311147D0 (en) | 1993-05-28 | 1993-07-14 | Long Ashton Research Station | Regulation of plant growth |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
BE1008987A3 (fr) | 1995-01-06 | 1996-10-01 | Robyn Pierre | Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre. |
JP3643863B2 (ja) | 1995-08-09 | 2005-04-27 | アークレイ株式会社 | 液体保持具とその製造方法 |
AU710818B2 (en) | 1996-03-01 | 1999-09-30 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
US6165739A (en) | 1996-03-13 | 2000-12-26 | Compucyte Corporation | Multiple simultaneous testing media |
AU4063697A (en) * | 1996-08-08 | 1998-02-25 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
CA2468374C (fr) * | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Derives de glp-1 |
AU4863797A (en) | 1996-11-12 | 1998-06-03 | Novo Nordisk A/S | Use of glp-1 peptides |
EP1047938A2 (fr) | 1998-01-12 | 2000-11-02 | Betagene, Inc. | Lignees cellulaires recombinees pour le criblage de medicaments |
ATE375752T1 (de) | 1998-03-06 | 2007-11-15 | Spectrx Inc | Integrierte gewebeporations-, flüssigkeitsammel- und analysevorrichtung |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
WO1999053064A2 (fr) | 1998-04-13 | 1999-10-21 | Modex Therapeutiques, S.A. | Techniques d'administration de glp-1 |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6267954B1 (en) | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
US6706159B2 (en) | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
ATE309818T1 (de) | 2000-03-08 | 2005-12-15 | Novo Nordisk As | Senkung des serum cholesterols |
DE10039643A1 (de) * | 2000-08-14 | 2002-02-28 | Max Planck Gesellschaft | Funktionalisierte Perylentetracarbonsäurediimide |
CZ308214B6 (cs) * | 2000-12-07 | 2020-03-04 | Eli Lilly And Company | GLP-1 fúzní proteiny |
CA2430651C (fr) | 2001-02-09 | 2010-10-12 | Wisconsin Alumni Research Foundation | Procede et structure permettant le guidage d'ecoulements microfluidiques |
US20020183253A1 (en) | 2001-02-22 | 2002-12-05 | Brazzell Romulus Kimbro | Method of treating ocular neovascularization |
US20030034147A1 (en) | 2001-05-31 | 2003-02-20 | Houck Glenn M. | Apparatus which eliminates the need for idling by trucks |
EP1412384B1 (fr) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Formulation stable de glp-1 modifie |
CN1363654A (zh) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法 |
WO2003010305A1 (fr) | 2001-07-27 | 2003-02-06 | Arhus Amt | Cellules souches immortalisées |
DE60228972D1 (de) | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
US20040143104A1 (en) | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
WO2003020201A2 (fr) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-melanges de polypeptide glp-1 et d'insuline basale |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7166208B2 (en) | 2004-03-03 | 2007-01-23 | Stephen Eliot Zweig | Apoenzyme reactivation electrochemical detection method and assay |
WO2003059372A2 (fr) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Utilisation combinee d'un compose glp-1 et d'un modulateur de complications diabetiques tardives |
WO2003058203A2 (fr) * | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Analogues de peptide-1 de type glucagon d'extension |
GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US20030143113A2 (en) | 2002-05-09 | 2003-07-31 | Lifescan, Inc. | Physiological sample collection devices and methods of using the same |
JP2006501820A (ja) | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法 |
WO2004078195A1 (fr) * | 2003-03-07 | 2004-09-16 | Ajinomoto Co., Inc. | Agent de conversion de cellule intestinale en cellule produisant de l'insuline et remede pour le diabete |
US6969166B2 (en) | 2003-05-29 | 2005-11-29 | 3M Innovative Properties Company | Method for modifying the surface of a substrate |
US7057116B2 (en) | 2003-06-02 | 2006-06-06 | Intel Corporation | Selective reference plane bridge(s) on folded package |
KR100758755B1 (ko) * | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Glp-1 유사체 융합 단백질 |
EP1498143A1 (fr) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Formulations auto-émulsifiantes et auto-microémulsifiantes pour l'administration orale de taxoides |
JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
EP1673464A2 (fr) | 2003-10-10 | 2006-06-28 | Novo Nordisk A/S | Conjugaison de peptides |
CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
WO2005072216A2 (fr) | 2004-01-20 | 2005-08-11 | The Curators Of The University Of Missouri | Viscosimetres moleculaires de biofluides sir support a usage un vitro et un vivo |
BRPI0507594A (pt) | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | polipetìdeos hìbridos com propriedades selecionáveis |
CN1934444A (zh) | 2004-03-05 | 2007-03-21 | 艾格麦迪卡瑞士股份有限公司 | 用于确定生理液体中的分析物浓度的分析物测试系统 |
AU2005231359A1 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
US20080300173A1 (en) * | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
DE602004023545D1 (de) | 2004-08-13 | 2009-11-19 | Egomedical Technologies Ag | Analyttestsystem zur bestimmung der konzentration eines analyten in einer physiologischen oder wässrigen flüssigkeit |
US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
CA2616551A1 (fr) | 2005-07-29 | 2007-02-15 | Amprotein Corporation | Agents therapeutiques chimeriques |
ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (fr) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Peptides à fusion GLP-1 associée à un/plusieurs polymères, leur production et utilisation |
EP1975176A1 (fr) | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Nouveaux peptides à fusion GLP-1, leur production et utilisation |
EP2163243A1 (fr) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Traitement de l'infarctus du myocarde (AMI) utilisant des cellules encapsulées codant et sécrétant des peptides GLP-1 ou analogues associés |
-
2005
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 EP EP05020718A patent/EP1767545B1/fr active Active
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 EP EP08021837A patent/EP2045265B1/fr active Active
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
-
2006
- 2006-09-22 EP EP10009718A patent/EP2261245A1/fr not_active Withdrawn
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Application Discontinuation
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 EP EP06792228A patent/EP1926748B1/fr not_active Not-in-force
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/fr active Application Filing
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 CA CA002619053A patent/CA2619053A1/fr not_active Abandoned
- 2006-09-22 EP EP09014513A patent/EP2174952A3/fr not_active Withdrawn
-
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
-
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
-
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
-
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG165414A1 (en) | Glp-1 ( glucagon-like peptide-1 ) fusion polypeptides with increased peptidase resistance | |
WO2008116648A3 (fr) | Nouveaux peptides de fusion glp-1, leur production et leur utilisation | |
Gupta | Glucagon-like peptide-1 analogues: an overview | |
WO2003033671A3 (fr) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
Mentlein | Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP | |
US20050137135A1 (en) | Novel analogues of glucose-dependent insulinotropic polypeptide | |
TW200611704A (en) | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | |
WO2007140284A3 (fr) | Modulateurs des récepteurs de glp-1 modifiés en n-terminal | |
EP2926825A1 (fr) | Agents thérapeutiques comprenant des peptides de type élastine | |
US20160194371A1 (en) | Fusion proteins comprising FGF-21 and GLP-1R agonist | |
EP2301962A3 (fr) | Invention concernant GLP-1 et l'exendine | |
WO2006121860A3 (fr) | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation | |
WO2006017688A3 (fr) | Polythérapie basée sur l’utilisation de protéines hybrides de transferrine contenant du glp-1 | |
WO2004094461A3 (fr) | Mimetiques du peptide 1 de type glucagon humain utilises dans le traitement du diabete et des pathologies apparentees | |
IL176541A0 (en) | Intranasal administration of glucose-regulating peptides | |
US20110288001A1 (en) | Biologically active proteins activatable by peptidase | |
AU2006213607A1 (en) | GIP analog and hybrid polypeptides with selectable properties | |
BR9913284A (pt) | Métodos para administrar peptìdeos insulinotrópicos | |
JP2011219488A (ja) | 選択可能な特性を有するハイブリッドポリペプチド | |
WO2007082264A3 (fr) | Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés | |
DK1953172T3 (da) | TRUNKERET GLUCAGON-LIGNENDE PEPTID-1 (sGLP-1) OG DETS FREMGANGSMÅDE OG ANVENDELSE | |
Green et al. | Lys9 for Glu9 substitution in glucagon-like peptide-1 (7–36) amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1 (9–36) amide and exendin (9–39) | |
Linderoth et al. | GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity | |
Chen et al. | Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues | |
Oskola et al. | Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4 |